As of Jun 29
| +0.08 / +0.32%|
The 7 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 43.00, with a high estimate of 60.00 and a low estimate of 20.00. The median estimate represents a +69.36% increase from the last price of 25.39.
The current consensus among 8 polled investment analysts is to Buy stock in Acorda Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.